Longitudinal Reporting: Evaluating the Same Patient at Multiple Scan Intervals

Having information about brain volumes at one-point-in-time can be a powerful tool in the evaluation of neurodegenerative diseases. However, personalized patient care does not end after one time point. It is an ongoing process that includes continuous monitoring, evaluation of care effectiveness, and potentially, adjustment to previous care decisions.

Volumetric brain measurements provide a great deal of valuable information to a physician, especially after an incident, or after a change in treatment. These are some of the questions that could be answered by a trained physician using the NeuroQuant® longitudinal reporting feature.

  • Is the brain volume deterioration continuing, may indicate that the treatment is not as effective as expected?
  • In dementia patients: Are the patient’s memory complaints from normal aging or has brain atrophy progressed?
  • In multiple sclerosis patients: Has the brain volume loss stopped? Is there increased damage from recent episodes?
  • Is the current treatment plan effective in slowing or stopping further neurodegeneration?

Longitudinal report case study:
The chart below shows the NeuroQuant results for a 77 year old patient with memory loss complaints. His hippocampal volume is smaller than expected for when normalized to age and gender and outside the 95 percentile (left graph), the inferior lateral ventricles are larger than expected when normalized for age and gender and outside the 95 percentile (right graph) and the hippocampal occupancy score (HOC) of the mesial temporal lobe is also outside the 95 percentile. These results show strong indications of hippocampal atrophy.

Cortechs.ai | Longitudinal Reporting: Evaluating the Same Patient at Multiple Scan Intervals

The chart below depicts the same patient two years later at 79 years old. NeuroQuant provides the same three brain structures measurements as before. The patient has had annual scans resulting in three data points for each brain structure. The visualization in one plot indicates the progression of the atrophy over time, and a physician can view the worsening hippocampal atrophy.

Cortechs.ai | Longitudinal Reporting: Evaluating the Same Patient at Multiple Scan Intervals

NeuroQuant provides the longitudinal reporting information in a single NeuroQuant volumetric output report. When multiple time point measurements of the same patient are available, the results are displayed on a single report, allowing physicians to see a clear progression of any changes to the patient’s relevant brain structures. The use of a single report allows the physician to quickly and easily evaluate any trend in the patient’s brain volume development.

NeuroQuant’s longitudinal reporting feature is a major component in the personalized care path that follows an initial evaluation. It provides physicians with more objective data to help with clinical assessments and when outlining possible clinical courses.

More Resources

08/19/2026

Brain Metastases Imaging Insights from SNO/ASCO 2026

Explore key insights from SNO/ASCO 2026 on brain metastases imaging, including lesion tracking, volumetric analysis, SRS workflows, and automated segmentation.

08/18/2026

Cortechs.ai Announces FDA Clearance for NeuroQuant® PET: Advancing Molecular Imaging for Cognitive Impairment

NeuroQuant® PET receives FDA 510(k) clearance, advancing quantitative PET imaging for cognitive impairment.

08/04/2026

Cortechs.ai Expands European CE Marking Across AI Imaging Platform, Accelerating Global Growth

Cortechs.ai expands EU CE Marking for the latest NeuroQuant®, NeuroQuant® Brain Tumor, and OnQ™ Prostate, advancing global AI imaging innovation

07/29/2026

Read Your Segmentations in the Same Space You Read the Study: Native Space Outputs in NeuroQuant v5.3.0

Review lesion segmentations directly on your original MRI images with NeuroQuant® v5.3.0.

07/23/2026

What AAIC 2026 Told Us About the Future of Dementia Imaging — And Where NeuroQuant Fits

Quantitative MRI brain volumetry with NeuroQuant.

07/09/2026

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration

Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai’s health system network
Scroll to Top